[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multicenter-study\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multicenter-study":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,72,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100638551","multi-omics-inflammatory-phenotype-for-abpa-recurrence-risk-prediction-100638551",false,"NCT07611838","Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction","Multi-Omics Data-Derived Inflammatory Phenotype for ABPA Recurrence Risk Prediction: A Multicenter Study","Inclusion Criteria:\n\n* Female and Male patients aged 18-80 years\n* diagnosis of Allergic Bronchopulmonary Aspergillosis ABPA accroding to the 2024 ISHAM Working Group Diagnostic Criteria\n\nExclusion Criteria:\n\n* Patients with malignant tumors or severe organ dysfunction (e.g., cardiac, cerebral, renal, etc.)\n* Patients with severe comorbidities, including active pulmonary tuberculosis, lung cancer, chronic heart failure (NYHA class Ⅳ), chronic kidney disease (CKD stage 5), decompensated cirrhosis, etc.\n* Patients with immunosuppressive status, such as HIV infection, long-term use of oral corticosteroids or immunosuppressive agents.\n* Pregnant or lactating women.\n* Patients with missing key data or incomplete medical records.","ALL","18 Years","80 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.",[25,26,27,28,29],"Allergic Bronchopulmonary Aspergillosis (ABPA)","Machine Learning","Multi-omics","Multicenter Study","Relapse",[31,29,26,28,27],"Allergic Bronchopulmonary Aspergillosis","RECRUITING","2026-05-28",{"date":35,"type":36},"2026-06-01","ACTUAL",{"date":38,"type":36},"2021-01-01",{"date":40,"type":21},"2028-12-31",{"name":42,"class":43},"Qianfoshan Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100594588","the-epidemiology-of-suicide-attempts-and-suicidal-thoughts-in-flanders-100594588","NCT07021404","The Epidemiology of Suicide Attempts and Suicidal Thoughts in Flanders","BC-03869","Inclusion Criteria:\n\n* Everyone who is admitted alive to the emergency department after a suicide attempt is included. All methods used during the suicide attempt are included. Regarding the method of suicide attempts, a distinction is made between self-injury (hanging, strangulation, drowning, stab and cut wounds, jumping from a height, etc.) and self-poisoning (ingestion of (psycho)pharmaceuticals, drugs, alcohol, chemicals, or other harmful substances).\n* Everyone who is admitted with suicidal thoughts\n\nExclusion Criteria:\n\n* Accidental overdose, e.g., someone taking medication for a medical condition without any intent to harm themselves\n* Alcohol intoxication without any intent to harm oneself\n* Accidental overdose involving party drugs\n* Individuals who were deceased upon arrival at the hospital due to suicide","12 Years",{"count":54,"type":21},50000,"1 Day","The objective of this study is to collect data in Flanders on the incidence of suicide attempts and suicidal ideation across various healthcare settings. The study also aims to assess the proportion of individuals who receive adequate aftercare following a suicide attempt and to systematically document the methods and means used in suicidal behavior.",[58,59,28,60,61],"Suicidal Ideation","Suicide Attempt","Epidemiological Study","Suicidal Behavior","2025-06-05",{"date":64,"type":36},"2025-06-15",{"date":66,"type":36},"2006-12-31",{"date":68,"type":21},"2033-03-31",{"name":70,"class":43},"University Hospital, Ghent",33,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":44},"100549980","phase-3-multicenter-clinical-trial-on-the-effectiveness-and-safety-of-instillation-of-bcg-and-alternative-bcg-protocols-for-intermediate-and-high-risk-non-muscle-invasive-bladder-cancer-100549980","NCT06441110","Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer","Multicentre Clinical Trial of the Efficacy and Safety of Tislelizumab in Combination With BCG Bladder Instillation in the Prevention of Postoperative Recurrence in Intermediate and High-risk Non-muscle Invasive Bladder Cancer","Inclusion Criteria:\n\n1. Voluntary participation in the trial with signed informed consent;\n2. Patients aged ≥18 and ≤75 years, regardless of gender, with an expected survival of ≥2 years;\n3. Histologically confirmed non-muscle-invasive bladder urothelial carcinoma with positive PD-L1 expression. According to the 2014 guidelines of the Chinese Urological Association (CUA), patients are assessed as having a medium to high risk of recurrence or progression. (For patients considering a second transurethral resection, they may be included in the study after completing the procedure and if pathology confirms medium to high risk non-muscle-invasive bladder urothelial carcinoma);\n4. Performance status score (Eastern Cooperative Oncology Group, ECOG) of 0-2;\n5. Completion of screening-related examinations (complete blood count, coagulation function, liver and kidney function, infectious disease screening, 12-lead ECG, urinary system ultrasound, pelvic MR, and tissue pathology examination), without surgical contraindications.\n\nExclusion Criteria:\n\n1. Any of the following conditions:\n\n   Immune deficiency or impairment (such as AIDS patients), current use of immunosuppressive drugs or radiation therapy that may cause systemic BCG disease reaction; allergy to BCG components; patients with fever and acute infectious diseases, including active tuberculosis or those undergoing anti-tuberculosis treatment; those with severe chronic cardiovascular or cerebrovascular diseases or chronic kidney disease;\n2. Concurrent urogenital system tumors or tumors in other organs;\n3. Muscle-invasive bladder urothelial carcinoma (stage T2 and above) patients;\n4. Patients who have received chemotherapy, radiotherapy, or immunotherapy within the past 4 weeks (except immediate postoperative bladder instillation chemotherapy);\n5. Pregnant or lactating women, women of childbearing age not using effective contraception, or those planning to conceive during the trial period (including male participant partners);\n6. Known or suspected intraoperative bladder perforation;\n7. Presence of gross hematuria prior to enrollment, suspected unhealed surgical wounds or damaged urinary mucosa;\n8. Severe urethral stricture preventing cystoscopy, history of bladder contracture, or functional bladder volume less than 100mL;\n9. Accompanying cystitis, or those who have received other bladder instillation medications and have severe bladder irritation signs expected to affect the assessment of this study;\n10. Patients with various mental disorders, severe coagulation function, liver and kidney function, hematopoietic function disorders, etc., that cannot tolerate surgical treatment;\n11. Participation in other drug clinical trials within 3 months before enrollment;\n12. Known or suspected opioid or alcohol dependence;\n13. Any condition that the researcher believes may increase the risk to the participant or interfere with the execution of the clinical trial.","75 Years",{"count":81,"type":21},76,"INTERVENTIONAL",[84],"PHASE3","Previous studies have reported the efficacy of Bacillus Calmette-Guérin (BCG) combined with other drugs for the treatment of bladder cancer. However, research on the combination of tislelizumab and BCG for bladder cancer treatment has largely been retrospective. Currently, ongoing clinical trials have not discussed the effectiveness of PD-1\u002FPD-L1 inhibitors combined with BCG instillation in reducing postoperative recurrence in intermediate-risk NMIBC. Therefore, this study aims to explore the clinical efficacy and safety of tislelizumab combined with BCG in the treatment of intermediate and high-risk NMIBC. For this purpose, investigators have established strict screening criteria to include eligible patients in the study and have recruited suitable patients from multiple medical centers.Investigators have also developed a meticulous implementation process and follow-up considerations, hoping to better verify the clinical efficacy and safety of the combined use of these two drugs.",[87,88,89,28,90,91],"Urinary Bladder Neoplasms","BCG Vaccine","Immunotherapy, Active","Treatment Outcome","Neoplasm Recurrence, Local","2024-06-03",{"date":94,"type":36},"2024-06-04",{"date":96,"type":36},"2023-06-01",{"date":98,"type":21},"2035-06-01",{"name":100,"class":43},"Fujian Medical University Union Hospital",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":109,"targetDuration":111,"studyType":22,"phases":4,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":44},"100408735","diagnosis-and-outcomes-evaluation-of-multicenter-patients-with-hfpef-using-multimodality-imaging-100408735","NCT04602338","Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging","Multimodality Imaging (Cardiovascular Magnetic Resonance Imaging, Echocardiography, and Nuclear Medicine Imaging) in the Screening, Diagnosis and Risk Stratification of Heart Failure With Preserved Ejection Fraction- a Multicenter Study.","Inclusion Criteria:\n\n* left ventricular ejection fraction (LVEF)≥50%；\n* N-terminal pro-b type natriuretic peptide (NT-proBNP)\\>220pg\u002Fml or b type natriuretic peptide (BNP) \\>80 pg\u002Fml;\n* symptoms and syndromes of heart failure;\n* At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler).\n\nExclusion Criteria:\n\n* Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc.\n* Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ;\n* Severe arrhythmia;\n* Severe primary cardiac valvular disease;\n* Restrictive pericardial disease;\n* Refuse to participate in the study.",true,{"count":110,"type":21},1000,"8 Years","The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are not well understood. It is difficult to recognize the subclinical changes of the cardiac in the early stage with conventional imaging techniques, and it is common to ignore the existence of the clinical alterations. This study aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF patients, based on the multi-modality (Magnetic resonance imaging- nuclear medicine imaging- echocardiography) imaging and multicenter study, combined with large data and artificial intelligence. This study will provide deep insights into the HFpEF in multicenter population.",[114,28],"Heart Failure, Diastolic",[116,117,118,119,120,121],"heart failure with preserved ejection fraction","cardiovascular magnetic resonance imaging","echocardiography","nuclear medicine imaging","early diagnosis","prognosis","2022-04-14",{"date":124,"type":36},"2022-04-18",{"date":126,"type":36},"2020-11-01",{"date":128,"type":21},"2028-06",{"name":130,"class":43},"Chinese Academy of Medical Sciences, Fuwai Hospital"]